AstraZeneca And Guangzhou Medical College Conduct Pulmonary Disease Study
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca Research Foundation and No. 1 Affiliated Hospital of Guangzhou Medical College have signed an agreement to jointly conduct basic research on chronic obstructive pulmonary disease. This represents the first MNC study on COPD in China. The hospital's national key laboratory of respiratory disease will undertake a two-year study into the reason for the disease's progress by observing 500 patients with COPD and comparing them with healthy controls. In China, COPD has an incidence of 8.4 percent but more than half the patients are not aware of the disease. Experts hope to instil the concept among healthcare workers that COPD is preventable and treatable. (Click here for more - Chinese language)